论文部分内容阅读
目的观察尤瑞克林治疗急性脑梗死的临床疗效及安全性。方法采用尤瑞克林静滴治疗急性脑梗死患者60例,观察其治疗前后临床疗效及安全性;用用国际卒中量表(NIHSS)评定临床神经功能缺损程度,Barthel指数量表(ADL)评定日常生活活动能力,改良Rankin Scale量表(mRS)评定残障程度;治疗前后检测肝肾功能、纤维蛋白原(FIG)、血小板(PLT),记录不良反应。结果60例急性脑梗死(ACI)患者基本治愈20例,显效38例,无效2例,总有效率96.7%,NIHSS、mRS及ADL评分均明显改善(P<0.01)。肝肾功等无明显变化。结论尤瑞克林治疗急性脑梗死安全、有效。
Objective To observe the clinical efficacy and safety of urelin in the treatment of acute cerebral infarction. Methods Sixty patients with acute cerebral infarction were treated with intravenous uricase. The clinical efficacy and safety were observed before and after treatment. The degree of clinical neurological deficit was assessed by the International Stroke Scale (NIHSS), and Barthel Index Scale (ADL) Activities of daily living, modified Rankin Scale (mRS) to assess the degree of disability; liver and kidney function, fibrinogen (FIG) and platelet (PLT) were detected before and after treatment, and adverse reactions were recorded. Results 60 cases of acute cerebral infarction (ACI) were basically cured in 20 cases, 38 cases were markedly effective and 2 cases were ineffective. The total effective rate was 96.7%. NIHSS, mRS and ADL scores were significantly improved (P <0.01). No significant changes in liver and kidney function. Conclusion Urelin is safe and effective in the treatment of acute cerebral infarction.